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The extracellular concentration of the two main neurotransmitters glutamate and GABA
is low but not negligible which enables a number of tonic actions. The effects of ambient
GABA vary in a region-, cell-type, and age-dependent manner and can serve as indicators
of disease-related alterations. Here we explored the tonic inhibitory actions of GABA
in Huntington’s disease (HD). HD is a devastating neurodegenerative disorder caused
by a mutation in the huntingtin gene. Whole cell patch clamp recordings from striatal
output neurons (SONs) in slices from adult wild type mice and two mouse models of
HD (Z_Q175_KI homozygotes or R6/2 heterozygotes) revealed an HD-related reduction
of the GABA(A) receptor-mediated tonic chloride current (ITonic(GABA)) along with signs of
reduced GABA(B) receptor-mediated presynaptic depression of synaptic GABA release.
About half of ITonic(GABA) depended on tetrodotoxin-sensitive synaptic GABA release, but
the remaining current was still lower in HD. Both in WT and HD, ITonic(GABA) was more
prominent during the first 4 h after preparing the slices, when astrocytes but not neurons
exhibited a transient depolarization. All further tests were performed within 1–4 h in vitro.
Experiments with SNAP5114, a blocker of the astrocytic GABA transporter GAT-3, suggest
that in WT but not HD GAT-3 operated in the releasing mode. Application of a transportable
substrate for glutamate transporters (D-aspartate 0.1–1mM) restored the non-synaptic
GABA release in slices from HD mice. ITonic(GABA) was also rescued by applying the
hyperagonist gaboxadol (0.33µM). The results lead to the hypothesis that lesion-induced
astrocyte depolarization facilitates non-synaptic release of GABA through GAT-3. However,
the capacity of depolarized astrocytes to provide GABA for tonic inhibition is strongly
reduced in HD.
Keywords: GABAergic synaptic transmission, astrocyte, GAT-3, ambient GABA, GABA(A) receptor, GABA(B)
receptor, presynaptic depression, Huntington’s disease
INTRODUCTION
In contrast to the low-affinity GABA(A) receptors in the postsy-
naptic density, extrasynaptic GABA(A) receptors populating the
somato-dendritic membrane of mature neurons display sufficient
sensitivity to report the presence of GABA at submicromolar con-
centrations (Semyanov et al., 2004; Farrant and Nusser, 2005;
Glykys and Mody, 2007a; Brickley and Mody, 2012). In addi-
tion, low concentrations of GABA in the environment of synaptic
terminals are detected by presynaptic GABA(B) receptors (Le
Feuvre et al., 1997; Kirmse and Kirischuk, 2006; Mapelli et al.,
2009; Dvorzhak et al., 2010; Laviv et al., 2010). Both signaling
pathways may interact for homeostatic adjustment of synaptic
vs. non-synaptic GABAergic input (Mody, 2005; Connelly et al.,
2013).
Tonic GABA actions vary strongly in a region—as well as cell-
type-specific manner (Semyanov et al., 2003; Song et al., 2011).
In the rodent striatum, where GABA-synthesizing cells constitute
the vast majority of the neuron population, tonic chloride cur-
rents via extrasynaptic GABA(A) receptors (termed ITonic(GABA))
were consistently recorded as depolarizing shifts in the baseline
currents in response to GABA(A) receptor block (Ade et al., 2008;
Janssen et al., 2009; Santhakumar et al., 2010; Cepeda et al., 2013).
Changes in vesicular transmitter release after bath-application of
a specific GABA(B) receptor-blocker present evidence for tonic
presynaptic GABA effects, at least under condition of reduced
GABA uptake (Kirmse et al., 2009). The indicators of tonic
extrasynaptic and presynaptic GABA actions can mutually vali-
date each other, although the presynaptic depression is probably
less sensitive (Kirmse et al., 2008).
It is obvious that the strength of tonic inhibition will not only
depend on the characteristics of the respective receptors (Scimemi
et al., 2005; Ransom et al., 2010) and the amount of “spillover”
after vesicular GABA release (Glykys and Mody, 2007b) but also
on the distribution and transport of GABA from and into the
extracellular space (Wu et al., 2007; Ransom et al., 2013). In the
present study, the focus will be placed on the role of the astrocytic
GABA transporter GAT-3 as a potential source of non-synaptic
GABA release (Yoon et al., 2012).
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A comprehensive description of the structure, cellular distri-
bution and function of GABA transporters (GATs) can be found
in (Borden, 1996; Dalby, 2003; Richerson andWu, 2003; Jin et al.,
2011a). Four different GATs are known, with somewhat confusing
nomenclature inmice vs. rat. The expression of GAT-1 and GAT-3
is brain-specific, where GAT-1 protein is preferentially localized
in neurons, notably in their presynaptic terminals (Radian et al.,
1990), and GAT-3 is preferentially localized on the processes of
astrocytes (Minelli et al., 1996; Ribak et al., 1996).
As other neurotransmitter transporters, GABA transporters
can reverse their transport direction (Wu et al., 2007).
However, the conditions necessary for reversal may vary in depen-
dence of the given stoichiometry. While a glutamate uptake cycle
through the major astrocytic transporter GLT-1 (EAAT-2) is asso-
ciated with an inward move of three Na+ and one proton and an
outward move of one K+, a GABA uptake cycle through GAT-3
only co-transports two Na+ and one Cl−. Thus, the driving forces
at resting membrane potentials are much lower for the GABA
transport. Reversal may therefore easily occur under a variety of
physiological as well as pathophysiological conditions.
In general, one can expect that excessive excitation leading to
membrane depolarization, loss of potassium, and elevation of
intracellular sodium levels will increase the likelihood that sites
of GABA uptake are converted into sites of non-synaptic GABA
release (Richerson and Wu, 2003). At the same time, glutamate
transporters might continue to operate in the uptake mode. Thus,
within a range of cellular perturbations, opponent glutamate and
GABA transport may form a basis of neuroprotection, as recently
suggested by Heja et al. (2012). These authors presented evi-
dence that high activity of astrocytic glutamate uptake facilitates
non-synaptic GABA release through GAT-3. Their hypothesis also
predicts that, due to co-localization of GLT-1 and GAT-3, a failure
in astrocytic glutamate uptake would affect the neuronal response
to non-synaptic GABA release from astrocytes.
A devastating neurological condition associated with insuf-
ficiency of astrocytic glutamate uptake is Huntington’s disease
(HD). HD belongs to the group of inherited polyglutamine dis-
orders that derive from a CAG triplet repeat expansion. The
pathologically expanded tract of glutamines is toxic and causes
neurodegeneration, especially in the striatum. At earlier stages of
the disease, the afflicted individuals suffer from emotional and
cognitive disturbances, but also from uncoordinated movements.
This state (Ross and Tabrizi, 2011; Ha and Fung, 2012) is also
known as chorea. Striatal neurons expressing a mutant form of
huntingtin are characterized by hyperexcitability (Dvorzhak et al.,
2013) and pathological spontaneous action potential generation
(Miller et al., 2011). Several studies have suggested that in the HD
striatum reduced glutamate uptake through GLT-1 may impair
the capacity of astrocytes to support normal levels of neuronal
activity (Lievens et al., 2001; Behrens et al., 2002; Miller et al.,
2008; Faideau et al., 2010; Petr et al., 2013), but it is not yet known
as to what extent tonic GABA effects, in general, and GAT-3
function, in particular, were altered in symptomatic HD.
In the present study, we have used two different mouse models
of HD to quantify the possible changes in tonic extrasynap-
tic and presynaptic GABA actions. The results presented here
will lead to the conclusion that ITonic(GABA) and tonic GABA(B)
receptor-mediated depression of synaptic GABA release are less
potent in HD because the HD-afflicted astrocytes have a reduced
capacity to release GABA via GAT-3.
MATERIALS AND METHODS
ETHICAL APPROVAL
The present experiments were performed in fully adult (315–450
days) wild-type mice from a colony of Z-Q175-KI provided
by the CHDI (“Cure Huntington’s Disease Initiative”) founda-
tion and R6/2 mice provided by Charles River GmbH Germany.
Every precaution was taken to minimize stress and to reduce
the number of animals used in each series of experiments.
The work described here has been carried out in accordance
with the EU Directive 2010/63/EU for animal experiments and
complies with the requirements for manuscripts submitted to
biomedical journals. The work was registered at the Office of
Health Protection and Technical Safety of the regional govern-
ment Berlin (Landesamt für Arbeitsschutz, Gesundheitsschutz
und Technische Sicherheit Berlin, T0448/12).
TRANSGENIC MICE
The Z-Q175-KI mouse line was created by Cerebricon
Ltd/Charles River Labs, Kuopio, Finland and CHDI Fndn.
Inc., Princeton, NJ, and provided by the Jackson Labs, Bar
Harbor, USA (ME #370437). It originated from the Q140
knock-in (KI) mouse described by Menalled et al. (2003) and
express a chimeric mouse/human exon 1 mhtt. The R6/2 mouse
line (B6CBA-Tg(HDexon1)62Gpb/3J, Jackson Labs, Bar Harbor,
ME #006494) was derived from the transgenic mouse line
generated by Mangiarini et al. (1996). The mice were genotyped
by PCR and analyzed for CAG length. Experiments were either
performed in Q175 homozygotes or in R6/2 heterozygotes and
their respective wild-type siblings. We shall refer to the normal
wild-type mice as “WT” and to mice carrying a mutant form of
huntingtin as “HD mice” or just “HD.” For more information
on the mice see Dvorzhak et al. (2013). Briefly, average CAG
length was 120 ± 0.2 (range = 114–127, n = 137) in R6/2 and
184.6 ± 0.7 (range = 172–195, n = 68) in Q175. The average age
was 78.0 ± 1.1 d, n = 91 vs. HD 75.0 ± 1.2 d, n = 77 (n.s.) in
R6/2 and 400.3 ± 2.6 d, n = 54 vs. 405.6 ± 4.9 d, n = 68 (n.s.) in
Q175. All of the Q175 mice were older than 1 year. Considering
the absence of sex- and age-dependent differences in the tested
parameters we have accordingly pooled the data from the WT
and HD cohorts.
SLICE PREPARATION
The animals were deeply anesthetized by inhalation of a mix-
ture of isoflurane and carbogen (95% O2 and 5% CO2) and
transcardially perfused with 60ml of ice-cold (∼4◦C) saline con-
taining (in mM): 125 choline chloride, 2 KCl, 1.25NaH2PO4,
25NaHCO3, 0.5 CaCl2, 7MgCl2, 10 glucose, 0.5 CaCl2, 7MgCl2
(pH 7.25, 305mosmol/l). The 1 year and older Q175 mice were
initially prepared in the same solution, but in a second series of
experiments (Figures 4, 5) the Q175mice were transcardially per-
fused with ice-cold saline before removing the brains from the
skull. The choline-based perfusion solution was supplemented
with 5µM glutathione, 500µM Na pyruvate, 2.8mM ascorbic
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acid, and 1µM of MK-801. The brain was removed quickly
(∼1min), separated into two hemispheres and transferred into
ice-cold oxygenated saline. Sagittal slices of 300µmwere prepared
with a vibrating microtome (Integraslice 7550PSDS, Campden
Instruments Ltd., Loughborough, UK) and then maintained for
at least 1 h in artificial cerebrospinal fluid (ACSF) that contained
(in mM): 125NaCl, 2 KCl, 1.25NaH2PO4, 25NaHCO3, 2 CaCl2,
1MgCl2, 10 glucose, 0.5 pyruvic acid, 0.005 glutathione, and 2.8
ascorbic acid(pH 7.35, 303mosmol/l).
SOLUTIONS AND CHEMICALS
During experiments, 10µM DNQX and 50µM DL-2-amino-
5-phosphonopentanoic acid (APV) were added to the ACSF to
block glutamatergic currents. The remaining postsynaptic cur-
rents were completely blocked by bicuculline methiodide (BMI,
25µM) or SR-95531 (gabazine, 10µM), but not by strychnine
(30µM), indicating their GABAergic nature. The following
pharmacological agents were obtained from Tocris (Bristol, UK)
and applied at indicated concentrations: gaboxadol or 4,5,6,7-
tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrochloride (THIP,
0.1-1µM), (2S)-3-(1S)-1-(3,4-dichlorophenyl)ethyl]amino-
2-hydroxypropyl](phenylmethyl)phosphinic acid (CGP55845,
CGP, 1µM), LY341495 (40µM and 0.1µM), 1-[2-[tris(4-
methoxyphenyl)methoxy]ethyl]-(S)-3-piperidinecarboxylic acid
((S)-SNAP5114, 40µM). Tetrodotoxin (TTX, 1µM) was
obtained from Alomone Labs (Jerusalem, Israel). All other
chemicals were from Sigma-Aldrich (Munich, Germany),
including 1-[2-[[(diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-
tetrahydro-3-pyridinecarboxylic acid hydrochloride (NO-711,
10µM), D-aspartic acid monosodium salt (D-Asp, 0.1-1mM).
Other concentrations are given in the Results section.
PATCH CLAMP RECORDING
For electrophysiological tests, slices were submerged into a perfu-
sion chamber with a constant flow of oxygenated ACSF. The flow
rate was set to 1–2ml min−1. Temperature during the recordings
was maintained at 26–27◦C. Preceding experiments at various
maintenance temperature (range = 23–30◦C) showed that under
the given conditions slices from animals >1 year were best main-
tained at this temperature, the quality criterion being the level
of neuronal membrane potentials at break-in, in addition to the
appearance of the slices. In HD mice, one could see debris from
degenerating axons in the globus pallidus and substantia nigra
suggesting some degree of neurodegeneration.
Pipette resistance was 3-6MOhm when filled with the fol-
lowing saline (in mM): 150KCl, 5NaCl, 0.5 CaCl2, 5 EGTA,
25HEPES, 2MgATP, 0.3GTP (for recording tonic chloride cur-
rents) and 100 potassium gluconate, 50 KCl, 5NaCl, 0.5 CaCl2,
5 EGTA, 25HEPES, 2MgATP, 0.3GTP (for recording IPSCs).
The calculated equilibrium potentials for chloride [ECl–] were 4
and −21mV, respectively.
Electrophysiological signals were acquired using an EPC-8
amplifier (List, Darmstadt, Germany), a 16-bit AD/DA board
(ITC-16, HEKA Elektronik, Lambrecht, Germany) and the soft-
ware TIDA 4.11 (HEKA Elektronik, Lambrecht, Germany). The
signals were sampled at a rate of 10 kHz and filtered at 3 kHz.
Liquid junction potentials were not corrected. In neurons, the
holding potential was set to −70mV which was close to the
resting membrane potential recorded in these cells in the cur-
rent clamp mode immediately after break-in. Access resistance
was monitored by applying pulses of −10mV. Cell capacitance
and access resistance values were obtained by fitting a mono-
exponential function to the capacitance transients. Only record-
ings with a series resistance below 30MOhm were accepted (in
typical cases series resistance amounted to 15-20MOhm). Series
resistance compensation was not applied. Cells exhibiting more
than a 20% change in the access resistance during an experiment
were discarded. Resting membrane potentials of neurons and
suphorhodamine-labeled astrocytes were measured immediately
after break-in.
IDENTIFICATION OF ASTROCYTES
Protoplasmic astrocytes were identified by staining with sulforho-
damine 101 (SR101) (Nimmerjahn et al., 2004). The original
protocol was modified to optimize the labeling in slices from
adult and, in case of HD, rather sick mice. Briefly, 30min after
preparation slices were transferred into oxygenized ACSF con-
taining 6µM SR101 and maintained at 37◦C for 10min. After
this the slices were washed and stored for at least 40min in
standard ACSF at room temperature. Astrocyte staining was visu-
alized under fluorescence optics using an excitation wavelength of
573 nm controlled by a monochromator system (polychrome V)
from Till Photonics (Gräfelfing, Germany). The dichroic mirror
(QMAX/DI580LP) and emission filter (QMAX/EM600-650) were
from Omega Optical, Brattleboro, VT, USA.
ELECTRICAL STIMULATION AND RECORDING OF UNITARY EPSCs
Unitary evoked excitatory postsynaptic currents (eEPSCs) were
elicited by intrastriatal microstimulation via a glass pipette filled
with ACSF as described before (Dvorzhak et al., 2013). Briefly,
glass pipettes filled with ACSF had a resistance of about 10MOhm
and were moved in the dorsal striatum in the vicinity of the
recorded neuron until the recording pipette detected a postsynap-
tic response. Sometimes neurons were filled with Lucifer Yellow
which helped to avoid positions that could lead to direct depo-
larization of dendrites. An isolated stimulation unit was used to
generate rectangular electrical pulses. Pulse duration was set at
0.5ms. Pulse intensity was adjusted to activate a synaptic response
at minimal intensity and with distinct threshold. Stimulation
was accepted as unitary if the following criteria were satisfied:
(1) eIPSC latency remained stable (<20% fluctuations), (2) low-
ering stimulus intensity by 20% resulted in a complete failure
of eIPSCs, (3) an increase in stimulus intensity by 20% neither
changed mean eIPSC amplitude nor eIPSC shape, (4) there was
no contamination by glutamatergic synaptic input. Typical cur-
rent intensities required for unitary stimulation ranged between
0.4 and 0.6µA. Paired pulses were delivered at an inter-stimulus-
interval of 50ms at a repetition frequency of 0.1–0.2Hz to
allow for full recovery of transmitter release after paired pulse
stimulation at an interval of 50ms.
Although there is no proof that only 1 axon had been stim-
ulated in any given case, we regard it as highly probable that
the responses induced by minimal stimulation were indeed “uni-
tary eIPSCs,” i.e., responses to activation of just one presynaptic
Frontiers in Neural Circuits www.frontiersin.org November 2013 | Volume 7 | Article 188 | 3
Wójtowicz et al. Tonic inhibition in Huntington’s disease
neuron. For the sake of simplicity, evoked IPSCs will in the follow-
ing be referred to as eIPSCs, assuming that in the vast majority of
cases we have dealt with unitary connections.
DATA EVALUATION AND STATISTICS
All data was evaluated off-line using TIDA 4.11 (HEKA
Elektronik, Lambrecht, Germany), IgorPro6.0 (WaveMetrics,
Lake Oswego, OR, USA), Prism 6.01 (Graphpad, San Diego,
CA, USA), SPSS 21 (SPSS GmbH Software, Munich, Germany).
ITonic(GABA)was defined as the difference of baseline currents
in the absence and presence of BMI (20µM). The size of
ITonic(GABA)was verified by plotting all-points histograms for 30 s
periods immediately before and during BMI application using a
custom-writtenmacro in IgorPro6.0 (WaveMetrics, Lake Oswego,
OR, USA). Gaussian functions were fitted to the part of the
distribution not skewed by synaptic events, and ITonic(GABA)
was determined as the distance between the two amplitude
peaks.
The quantitative results are presented as mean ± s.e.m. The
error bars in the figures indicate s.e.m. Data points and means
from HD mice are presented with gray fill. The numbers in
brackets are the number of tested neurons. Normality of data
distributions was evaluated by the Kolmogorov–Smirnov or the
Shapiro–Wilk test. Differences between means were determined
by paired or unpaired t-test (normally distributed data) and
Wilcoxon matched-pairs signed rank test or Mann–Whitney
test (not normally distributed data). Bonferroni correction was
implemented in case of multiple comparison tests. One-Way
ANOVA (normally distributed data) or Kruskal–Wallis statistics
(not normally distributed data) was used for differences between
3 groups of data from different cells. Two-Way ANOVA with
post-hoc Bonferroni correction was performed for experiments
in the classical 2 × 2 design, with 2 independent factors (geno-
type and treatment). Fitting of regression curves to data points
was performed on the basis of the Spearman test. The aster-
isks in the figures indicate the following: ∗p < 0.05, ∗∗p < 0.01,
and ∗∗∗p < 0.001.
RESULTS
THE GABA(A) RECEPTOR-MEDIATED TONIC CHLORIDE CURRENT AND
THE GABA(B) RECEPTOR-MEDIATED DEPRESSION OF SYNAPTIC GABA
RELEASE AS REPORTERS OF AMBIENT GABA CONCENTRATION IN THE
MURINE STRIATUM
Extrasynaptic GABA(A) receptors and presynaptic GABA(B)
receptors display high affinities for GABA, the respective EC50
values in slice preparations being 0.1–0.25µM (Dvorzhak et al.,
2010) and 1.5–5µM (Le Feuvre et al., 1997). They are there-
fore well-suited to indicate the presence of extracellular GABA
concentrations ([GABA]ec) in the lower micromolar range.
Moreover, the combined use of the two indicators helps to
mutually validate the obtained results. Figure 1 illustrates this
experimental approach when applied to WT and HD SONs.
FIGURE 1 | HD-related differences in tonic GABA action in the striatum.
(A) Specimen records of ITonic(GABA) from SONs in slices from 1 year old WT
and Q175 HD. Experiments in the presence of DNQX (10µM), APV (50µM),
LY341495 (40µM); no K+ channel block. Graphs on the right: Gaussian fits to
all-points histograms derived from 30 s recording periods under control
conditions and in the presence of BMI. The difference between the peaks of
the fitting curves represents the amplitude of ITonic(GABA) as plotted in (B). (B)
ITonic(GABA) obtained from WT (empty symbols) and HD mice (filled symbols).
Note similar results in the two mouse models of HD. Significance levels
according to Mann–Whitney-test. (C) Sample traces to illustrate the
differential effects of GABA(B) unblocking with CGP (1µM) in WT and HD.
Records under similar conditions as in panel (E). (D,E) Quantification of
results for eIPSC amplitude and PPR. Note lack of CGP effect in HD mice and
similar results from Q175 and R6/2 WT. Significance levels according to
paired t-tests. The asterisks denote the following: ∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.001.
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The GABA(A) receptor-mediated ITonic(GABA) was defined as
the baseline current shift recorded during the application of
20µM of BMI (Figure 1A). The experiments were performed at
a high intracellular chloride concentration without addition of
potassium channel blockers and rendered similar results in WT
SONs from the Q175 and the R6/2 colony (Figure 1B).
Tonic GABA(B) receptor-mediated effects were determined in
a similar manner, but by bath application of the GABA antagonist
CGP at a concentration of 1µM. This concentration is suffi-
cient to block saturating GABA(B) effects of GABA (Le Feuvre
et al., 1997). CGP-induced changes in the paired pulse ratio
(PPR), in addition to changes in the amplitude of unitary evoked
IPSCs (eIPSCs), indicate a GABA(B)-dependent depression of
synaptic GABA release (see Dvorzhak et al., 2013, for details).
Recordings of eIPSCs from adult WT SONs (Figure 1C) illustrate
that synaptic GABA release is indeed reduced by tonically active
GABA(B) receptors. The typical finding after CGP administra-
tion was an increase of the first eIPSC and a decrease of the PPR
(Figures 1C–E). Again, similar results were obtained in WT from
the Q175 and R6/2 colonies.
Together, these results are in line with previous evidence sug-
gesting a role of ambient GABA in the regulation of activity levels
in the rodent striatum (Ade et al., 2008; Kirmse et al., 2008;
Janssen et al., 2009; Santhakumar et al., 2010; Cepeda et al., 2013).
HD-RELATED DIFFERENCES IN TONIC GABA ACTIONS
Under standard recording conditions, the tonic actions of GABA
were weaker in HD. Again, this applies to the GABA(A) receptor-
mediated ITonic(GABA) (1A, B) and to the GABA(B) receptor-
mediated presynaptic depression of synaptic GABA release
(Figures 1C–E). Moreover, results obtained in Q175 were repro-
duced in R6/2 (Table 1).
The following experiments were aimed at clarifying the
origin of the HD-related differences in tonic GABA actions.
Table 1 | Characteristics of I(Tonic)GABA in two mouse models of HD.
WT HD p
Mean ±SE N Mean ±SE N
Q175 SERIES 1
Standard 30.7 2.6 30 21.9 2.1 37 0.0028
+ TTX 1µM 17.9 2.1 15 11.7 1.2 23 0.0016
+ TTX + NO-711 10µM 43.2 6.9 12 68.0 8.3 18 0.0306
Q175 SERIES 2
+ TTX 1µM 34.1 4.2 12 16.9 1.5 13 0.0003
+ TTX + SNAP5114 40µM 22.9 3.2 13 35.0 4.2 7 0.0771
+ TTX + D-Asp 0.1mM 32.7 5.4 15 38.0 4.5 18 n.s.
R6/2
Standard 36.1 5.2 11 15.7 3.0 14 0.0018
+ TTX 1µM 16.1 3.2 9 4.7 2.2 9 0.0078
+ TTX + NO-711 10µM 55.4 10.6 11 83.8 11.0 11 0.0648
+ TTX + D-Asp 0.1mM 12.4 1.6 11 15.9 3.9 13 n.s.
The significance levels of the differences between means from WT and HD apply
to Mann–Whitney tests.
First we addressed the question as to what extent action
potential-(AP)-dependent synaptic GABA release contributed to
the ambient GABA level that maintains ITonic(GABA). The results
of AP block with TTX (1µM) are presented in Figures 2A,B.
It can be seen that in both HD models, TTX significantly
reduced the amplitude of ITonic(GABA) suggesting that synapti-
cally released GABA is a major determinant of the ambient
GABA concentration. However, the differences between WT
and HD SONs remained. We therefore concluded that extrasy-
naptic release of GABA can play a role in the regulation of
ITonic(GABA).
Next we examined the effects of NO-711 (10µM), a blocker
of the predominantly neuronal GABA transporter GAT-1. Block
of GAT-1 was found to increase ITonic(GABA), particularly in the
HD mice, suggesting that the neuronal GABA transport operates
in the uptake mode. The results also indicate that in HD mice,
the tonic GABA effect is not limited by the availability of extrasy-
naptic receptors. Again, the results were similar in Q175 and R6/2
(Figures 2A,B, Table 1).
A POSSIBLE DEPENDENCE OF ITONIC(GABA) ON THE STATE OF
ASTROCYTES
Since all results were obtained from acutely prepared brain slices,
we had to address the caveat that the obtained data were influ-
enced by the preparation procedure, recording conditions and/or
the recovery dynamics after slicing. Indeed, years ago we have
reported results from immature rat (Meier et al., 2003) indicat-
ing that slicing and tissue maintenance in vitro stimulates a PKC-
and Ca-dependent process of GABAergic synaptogenesis. One has
to assume that the acute slice approach includes an acute response
to lesion. We therefore considered the possibility that the pertur-
bation of the tissue and the recovery dynamics after preparing
the slices might differentially affect the size of Itonic(GABA)in WT
FIGURE 2 | Influence of synaptic release and GAT-1 activity on
ITonic(GABA). Recording conditions and supplements as in Figure 1A. (A,B)
Results from two different types of HD mice. TTX (1µM) reduces
ITonic(GABA)without abolishing the HD-related difference. Block of GAT-1 with
NO-711 (10µM) increases ITonic(GABA). Note significantly stronger effect of
NO-711 in HD mice (filled bars). In both graphs, the data sets of the 6
columns were independent, not paired. In the 3 groups for Control, TTX,
and TTX+NO-711 the means from WT vs. HD were compared according to
Mann–Whitney tests (see Table 1 for more details). In addition, we have
performed Kruskal–Wallis statistics (KWS) to compare the differences
between Control, TTX, and TTX plus NO-711 in WT and HD. The respective
values were as follows. Q175 WT: KWS = 15.23, p < 0.001; Q175 HD:
KWS = 50.91, p < 0.0001. R6/2 WT: KWS = 12.40, p < 0.01; R6/2 HD:
KWS = 23.94, p < 0.0001. The asterisks denote: ∗p < 0.05, ∗∗p < 0.01,
and ∗∗∗p < 0.001.
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and HD mice. But what is the cellular basis of this differential
reaction?
As a very first step toward answering this question we exam-
ined the time dependency of ITonic(GABA) in Q175 WT and
HOMs (Figures 3A,B). It turned out that both in WT and HD
SONs ITonic(GABA) was larger during the first 4 h after cutting
the slices. Next we examined the membrane potentials (Vm)
of neurons (Figures 3C,D) and astrocytes (Figures 3E,F) and
found relatively stable neuronal Vm (albeit lower in HD), but
a very pronounced time dependency of astrocytic Vm. Thus,
high amplitudes of ITonic(GABA) coincided in time with astro-
cyte depolarization. This finding is consistent with two conclu-
sions: (i) lesion-induced astrocyte depolarization promotes the
reversal of the astrocytic GABA transporter GAT-3; (ii) in HD,
an additional mechanism attenuates the non-synaptic release of
GABA from astrocytes. In any case, the HD-related differences
in ITonic(GABA)cannot be attributed to differences in the electrical
driving force for astrocytic GABA release.
DEPENDENCY OF TONIC GABA ACTIONS ON THE ASTROCYTIC GABA
TRANSPORTER GAT-3
To further validate the role of the astrocytic GABA transporter
GAT-3 slices were for at least 7min incubated in the GAT-3-
specific blocker SNAP5114 (40µM). All recordings were per-
formed in Q175, within the first 4 h after slicing and in the
presence of TTX. Figures 4A,B presents the results of the exper-
iments with SNAP5114. Interestingly, SNAP5114 had opposite
effects in WT and HD SONs. In WT, SNAP tended to reduce
ITonic(GABA)while SNAP5114 treatment of HD slices resulted in a
significant increase. These results support the conclusion that in
WT, but not in HD mice, GAT-3 contributes to ITonic(GABA) and
operates in the releasing mode. The weaker tonic GABA action in
HD may then reflect the loss of GAT-3-dependent GABA release
from astrocytes.
Would this hypothesis be supported in the experiments with
CGP? Figures 4C–E presents the results. Indeed, SNAP5114
increased the amplitude of the 1st eIPSC and decreased the PPR,
FIGURE 3 | ITonic(GABA)in WT and Q175 HOMs at different times after
slice preparation. (A) Sample traces from 2 different WT SONs from
the Q175 colony; age: 55 weeks. Experiment in the presence of DNQX
(10µM), APV (50µM), LY341495 (40µM); no K channel block;
Vh = −70mV, ECl = 4mV. On the right: Gaussian fits to all-points
histograms derived from 30 s recording periods under control conditions
and in the presence of BMI. The difference between the peaks of the
fitting curves represents the amplitude of ITonic(GABA)as plotted in (B).
(B) Average values of ITonic(GABA)obtained from WT (empty bars) and
Q175 HD (filled bars) at variable time after preparation. The differences
between 2 and 6 h values were significant for WT at p = 0.0007 and
for HD at p = 0.005 (Mann–Whitney test). (C,D) Plots of neuronal
membrane potential against time in vitro. Note absence of
time-dependency in WT or HD (C), but significantly lower average
membrane potentials in the >4h HD group. (E,F) Plots of astrocytic
membrane potentials against time in vitro. Note that with time
astrocytic membrane potentials shift toward more negative values (E),
without any difference between WT and HD (F). The significance levels
in (D,F) refer to Mann–Whitney tests. The asterisks denote the
following: ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
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FIGURE 4 | HD-related differences in the effect of SNAP5114 on
ITonic(GABA)and presynaptic depression of evoked GABA release. (A)
Sample traces of ITonic(GABA)from a Q175 WT and HD SONs. Recordings in
the presence of TTX (1µM), CGP (1µM), DNQX (10µM), APV (50µM), and
LY341495 (40µM). Note opposite effects of GAT-3 block with SNAP5114
(40µM) in WT and HD. (B) Quantification of results from Q175 WT and HD.
Significance level according to 2-Way ANOVA with subsequent Bonferroni
correction for four comparisons. Normality was verified by the
Kolmogorov–Smirnov test. The ANOVA table gave the following results.
Interaction: F(1, 41) = 14.51, p = 0.0005; Genotype: F(1, 41) = 0.0683,
p = 0.7951, n.s.; Treatment with SNAP5114: F(1, 41) = 0.4032, p = 0.5290,
n.s. (C–E) Experiments in R6/2 WT and HD. Additions: APV 50µM, DNQX
20µM, LY341494 40µM. (C) Records of averaged eIPSCs under the
indicated conditions. Note that in WT, but not HD, SNAP5114 removed a
presynaptic depressant effect, as indicated by the significant decrease of the
PPR (E). Significance levels according to paired t-tests (comparison Control
vs. SNAP) and unpaired t-tests (comparison WT vs. HD). The asterisks
denote the following: ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
as it is to be expected when GAT-3 is blocked in the releasing
mode. HD preparations lacked this effect.
DEPENDENCY OF TONIC GABA ACTIONS ON GLUTAMATE
TRANSPORTER ACTIVITY
The HD-related deficiency of astrocytic GABA release under
condition of strong depolarization could reflect the weakness
of astrocytic glutamate uptake and the resultant change in the
local sodium gradient as a cause of GAT-3 reversal. The experi-
ments of Heja and colleagues (Heja et al., 2009, 2012) illuminated
the dependency of the astrocytic GABA transporter GAT-3 on
the state of glutamate transporters. In the rodent hippocam-
pus, GAT-3 and GLT-1 (EAAT-2) are co-localized (Heja et al.,
2012) and therefore exhibit a significant overlap of the respec-
tive intracellular [Na+] domains. The Na+ influx associated with
glutamate uptake by GLT-1 was regarded as a prerequisite for the
calcium-independent GABA release by GAT-3 from astrocytes.
Astrocytic depolarization and astrocytic glutamate uptake may
jointly drive the non-synaptic release of GABA from astrocytes.
While the former condition was present both in WT and in HD,
the latter was absent in HD.
If correct, stimulation of glutamate uptake with D-aspartate
might enhance non-synaptic GABA release and therefore pro-
mote tonic inhibition in HD. To test for this possibility, slices
from Q175 WT mice were treated for 10min with 0.1mM of D-
aspartate (Figure 5A). This had little effect in WT mice (data not
shown), but in HD it produced a highly significant increase of
ITonic(GABA) (Figure 5B). In normal mice treatment with 1mM
of D-aspartate produced a significantly higher ITonic(GABA) if
compared to Control (without D-asparate) or treatment with
SNAP5115 (Figure 5C), thereby rendering further support to the
conclusion that astrocytes indeed release GABA via GAT-3 if
glutamate transporter activity is high enough.
Finally, we explored the possibility that the tonic GABA(B)-
mediated depression of synaptic GABA release is also influenced
by glutamate transporter activity. The experiments were per-
formed in slices from R6/2 HD mice (Figures 5D–F). In one
and the same cell, synaptic transmission was sequentially tested
under control condition, after 5min of bath application of D-
aspartate (1mM) and 1mM of D-aspartate supplemented with
the GABA(B) receptor blocker CGP (1µM). It can be seen that
D-aspartate reduced the amplitude of eIPSCs and increased the
PPR. This effect was prevented by CGP, supporting a GABA(B)-
dependent mechanism that is maintained by astrocytic GABA
release via GLT-1/GAT-3 clusters.
The results with D-aspartate are interesting because they show
that stimulation of glutamate uptakemay restore astrocytic GABA
release and therefore help to repair the imbalance between extra-
cellular glutamate and GABA levels in HD. They also suggest
that in HD, extrasynaptic GABA(A) and presynaptic GABA(B)
receptors are present at sufficient densities to obtain a functional
recovery within few minutes.
RESCUE OF ITONIC(GABA) WITH THIP (GABOXADOL)
Pharmacological rescue of ITonic(GABA) is important, but it might
be advantageous to achieve its recovery without a reduction of
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FIGURE 5 | Effects of D-aspartate on ITonic(GABA) and GABA(B)
receptor-mediated presynaptic depression of synaptic GABA release.
(A–C) Experiment with Q175WT and HD. Recordings in the presence of DNQX
(10µM), APV (50µM), and LY341494 (40µM). (A) Sample traces from a Q175
HD SON in the absence and presence of D-aspartate (0.1mM). Note the larger
ITonic(GABA)after 10min treatment of HD slices with D-aspartate. (B)
Quantification of the results fromQ175HDmice. Significance level according to
Mann–Whitney test. (C) ITonic(GABA)ofWTSONs treatedwith 1mMD-aspartate
for 5min. Note the highly significant decrease in the presence of SNAP5115
(40µM). Significance level according to One-Way ANOVA with post-hoc
Bonferroni correction [F(2, 31) = 6.603, p = 0.0041]. The data sets represented
in the three columns are independent, not matched. (D–F) eIPSCs in R6/2 WT
and HD SONs in the presence of APV (50µM), DNQX (20µM), and LY341494
(40µM). (D) Records of averaged eIPSCs from one and the same HD SON
under the indicated conditions. Note the rescue of tonic GABA(B)-mediated
depressionof synapticGABA release inHDafter treatment of 1mMD-aspartate
for 5min. (E,F)Quantification of the results fromHDSONs tested for changes in
eIPSC amplitude (E) and PPR (F) in the presence of D-aspartate andD-aspartate
plus CGP. The indicated differences between Control and D-aspartate reflect
the amount of tonic presynaptic depression of synaptic GABA release
according to Wilcoxon’s matched-pairs signed rank test after Bonferroni
correction for multiple comparison. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
synaptic GABA release. We therefore examined the effects of
the delta-subunit-specific GABA(A) receptor hyperagonist THIP
(Figures 6A,B). The latter was applied at least 5min prior to
addition of BMI. The records were performed in the presence
of TTX, DNQX, APV, and LY341495. It was found that in HD
about 0.33µM of THIP were sufficient to restore ITonic(GABA) to
the WT level (Figure 6C). As it cannot be excluded that THIP
at higher concentrations activated both extrasynaptic and synap-
tic GABA(A) receptors, we estimated the average amplitudes of
miniature IPSCs expecting an IPSC decrease if part of the recep-
tors were occupied by THIP. However, no significant difference
was found between the IPSC amplitudes recorded in the absence
of THIP and THIP at a concentration of 0.33µM. Thus, applica-
tion of THIP might be another means to rescue tonic inhibition
in the striatum afflicted by HD.
DISCUSSION
Our experiments demonstrate that symptomatic HD is associ-
ated with a weakness of tonic GABA action and illuminate a so
far neglected pathophysiological element of HD in astrocytes,
the incapacity of GAT-3 to release GABA under condition of
astrocyte depolarization. The weakness of non-synaptic GABA
release from astrocytes in HD was not only reflected by the
lower amplitudes of ITonic(GABA) but also by the reduced strength
of GABA(B)-mediated presynaptic depression of synaptic GABA
release. Interestingly, treatment of slices with an exogenous sub-
strate of glutamate transport rescued non-synaptic GABA release
supporting the hypothesis that GAT-3 activity is coupled to
astrocytic glutamate transport (Heja et al., 2009, 2012).
REDUCED EXTRACELLULAR GABA CONCENTRATION IN HD?
Several attempts have been made to determine transmitter con-
centrations in postmortem normal and HD brains and by dial-
ysis and HPLC of animal preparations. A pioneer study by
Spokes et al. (1979) reported an unchanged GABA concen-
tration in the postmortem HD striatum despite a significant
decrease in the activity of glutamate decarboxylase. Later stud-
ies described a massive decrease of [GABA]ec in the striatum
(Ellison et al., 1987) and globus pallidus of choreic patients
(Kanazawa et al., 1985) and in mice treated with quinolinic acid,
an earlier model of HD (Ellison et al., 1987). However, to mea-
sure ambient transmitter concentrations under resting conditions
and independently of synaptic GABA release, it might be bet-
ter to take advantage of endogenous high affinity receptors (Le
Feuvre et al., 1997; Dvorzhak et al., 2010), unless the transmitter
receptors themselves set limits to the detection of extracellu-
lar transmitters. This was not the case here, since in HD slices
with GAT-1 block or treatment with D-aspartate ITonic(GABA)
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FIGURE 6 | Rescue of ITonic(GABA) in R6/2 HD mice by bath application
of THIP (gaboxadol) at a concentration of 0.33µM. (A,B) Specimen
records in the absence (A) and presence (B) of delta subunit specific
GABA(A) receptor hyper-agonist THIP (0.1µM, 0.33µM, and 1µM). The
recording conditions were similar to those in Figure 1. Experiments were
performed in the presence of TTX (1µM), DNQX (10µM), APV (50µM),
LY341495 (40µM); no K channel block; Vh = −70mV, ECl = 4mV. THIP was
applied through a slow drug delivery system to the bath solution (exchange
time ca. 1min). (C) Quantification of the results. The asterisks denote the
following: ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001. The comparison
between WT and HD was performed by the Mann–Whitney test. The THIP
effect on HD SONs was tested by One-Way ANOVA (multiple comparison
against the “THIP0” group) and resulted in F(3, 33) = 9.731, p < 0.0001 for
the THIP concentrations 0, 0.1, 0.33, and 1µM.
amplitudes were even higher than in the respective WT
controls.
Nonetheless, it would be premature to exclude the possi-
bility that cell-type-specific differences/changes in the expres-
sion of transmitter receptors add to the presently observed
HD-related differences. It is known that in the adult brain,
ITonic(GABA)primarily depends on GABA(A) receptors containing
a delta subunit (Stell et al., 2003). The latter is likely to be more
abundant in D1-expressing SONs (Santhakumar et al., 2010).
Indeed, in the absence of TTX, HD-related differences might be
more prominent in D2 SONs (Cepeda et al., 2013).
ASTROCYTIC GABA RELEASE?
In the rodent striatum 95% of the neurons express a GABAergic
phenotype, and interneurons together with other SONs establish
an extensive coverage with GABAergic synapses (Wilson, 2007;
Tepper et al., 2008). Striatal slices of WT and HD origin exhibit
AP-dependent spontaneous activity (Dvorzhak et al., 2013). It
is therefore not surprising that a major part of ITonic(GABA)
depended on AP-mediated synaptic release of GABA. The present
experiments showed, however that in both HD models the dif-
ference between WT and HD persisted after exclusion of AP-
dependent synaptic GABA release with TTX.
GABA of non-synaptic origin might be provided through the
GABA transporters GAT-1 and GAT-3 [see Jin et al. (2011a)
for a recent comprehensive review on data from basal ganglia].
However, previous results from the normal rodent striatum sug-
gested an increase of [GABA]ec after pharmacological block of
GAT-1 (Waldmeier et al., 1992; Kirmse et al., 2008). This result
is now confirmed and extended by showing that the NO-711-
induced increase of GABA uptake was even larger in HD.
The remaining possibility is that GABA is provided by astro-
cytes. The concept of gliotransmitter release in a voltage- and/or
calcium-dependent manner has already received broad support.
It is known that astrocytes release amino acids (glutamate,
D-serine), nucleotides (adenosine) and neuropeptides (brain-
derived neurotrophic factor, natriuretic peptide) and thereby
modify the activity of neighboring neurons and their synaptic sig-
nals (Parpura and Zorec, 2010). GABA is seldom on the list of
gliotransmitters (but see Glykys and Mody, 2007b; Angulo et al.,
2008), possibly because astrocytes lack the respective enzymes
glutamate decarboxylase, GAD65 and GAD67. However, there is
a GAD-independent form of GABA synthesis from putrescine
(Seiler et al., 1979; Angulo et al., 2008; Heja et al., 2012). In addi-
tion, GABA could also be shuttled from sites of GABA uptake to
sites of GABA release, similar to the spatial potassium buffering of
glial cells (Lux et al., 1986; Reichenbach, 1991). GABA immunola-
bel was found in GFAP-positive hippocampal astrocytes (LeMeur
et al., 2012).
Previous studies on the role of glial GABA transporters in the
rodent brain have yielded somewhat controversial results. Keros
andHablitz (2005) examined the function of GAT-3 andGAT-1 in
the juvenile rat cerebral cortex and found that GAT-3 contributes
little to the regulation of inhibition unless GAT-1 is blocked with
NO-711. In this case, GAT-3 and GAT-1 were thought to oper-
ate synergistically in the uptake mode with the prediction that
the presence of SNAP-5114 should enhance ITonic(GABA) as well
as GABA(B)-mediated presynaptic depression of evoked IPSCs.
Results supporting this notion were obtained in a previous study
from our own lab based on recordings from striatal output
neurons (SONs) in juvenile normal mice (Kirmse et al., 2009).
Support for a GAT-3-dependent enhancement of inhibition
under normal conditions was derived from another study of the
rodent cerebral cortex, where recordings were made in layer V
pyramidal neurons (Kinney, 2005). In this case, SNAP-5114 was
found to increase the amplitude of eIPSCs suggesting a decrease of
GABA(B) receptor-mediated depression of synaptic GABA release
when GAT-3 is not active. In recordings from globus pallidus neu-
rons, SNAP-5114 was also found to increase eIPSC amplitudes
(Jin et al., 2011b).
A recent study on the role of GAT-3 in the hippocampus
was performed in freely moving rats using microdialysis with
subsequent HPLC measurement of GABA concentration in the
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acquired probes (Kersante et al., 2013). This study showed a con-
tribution of GAT-3 to GABA uptake when GAT-1 was blocked. No
evidence was found for astrocytic GABA release.
As the state of astrocytes in a given slice preparation can have a
major impact on the strength of glutamate uptake, on one side,
and ambient GABA concentrations, on the other side, it may
become necessary to provide some functional checkpoints from
astrocytes to compare the results obtained on tonic GABA actions
under specific experimental settings.
RESCUE OF FUNCTION IN HD
It is known for more than a decade that astrocytes are affected by
HD (Vonsattel and DiFiglia, 1998; Faideau et al., 2010). The so
far most prominent functional deficit ascribed to astrocytes is the
deficiency of glutamate uptake (Lievens et al., 2001; Behrens et al.,
2002; Petr et al., 2013) and the resultant elevation of extracellular
glutamate concentration in the striatum (Arzberger et al., 1997;
Lee et al., 2013).
The present experiments add a new facet to the pathophys-
iology of HD by demonstrating an HD-related switch in the
polarity of GAT-3 action. Our results predict that block of the
non-physiological GABA uptake in HD would, within few min-
utes, restore the characteristics of tonic GABA actions toWT level.
SNAP5114 is a nipecotic acid derivative with “moderate affinity
and selectivity for the cloned humanGAT-3” (Dhar et al., 1994). It
has an IC50 of about 5µM for GAT-3, 20µM for GAT-2, 140µM
for BGT-1, and 400µM for GAT-1. Should more effective and
selective blockers of GAT-3 become available, it might become
worthwhile to examine the capacity of GAT-3 to alleviate motor
symptoms of HD.
At present, the easiest way to restore ITonic(GABA) seems to
be the application of gaboxadol (THIP). This compound is
an already well-characterized delta-subunit-specific GABA(A)
hyperagonist and has for some time been considered for treat-
ment of insomnia (Wafford and Ebert, 2006). In view of the
presently discovered HD-related deficit in ITonic(GABA), the ques-
tion arises whether HD patients can benefit from this drug.
Unfortunately, in a short (2 weeks) clinical trial on four patients
with choreatic and one patient with hypokinetic-rigid type of
HD, gaboxadol failed to provide the expected benefits but merely
caused sleepiness and unsteadiness of gait (Foster et al., 1983).
Finally, our results with D-aspartate underscore the need to
stimulate/recover the function of glutamate transport. A promis-
ing agent along this line is the antibiotic ceftriaxone (Sari et al.,
2010). Further experiments will show to what extent this drug can
restore tonic GABA actions in case of symptomatic HD.
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